IXICO provides software solutions and services to deliver imaging biomarkers used in clinical trials, research studies and health care diagnostics. It plans to lead a three-year collaborative project to develop a digital healthcare platform that combines computer-based memory and cognitive tests with computerized MRI analysis to produce automated diagnostic reports for dementia. The platform aims to open advanced investigative techniques to non-specialist doctors, reduce time to dementia diagnosis by 15 months, and increase diagnosis rates toward the Prime Minister’s Dementia Challenge target of 80%. IXICO will use a £2.1m grant from the government-backed Biomedical Catalyst to accelerate translation of scientific ideas into commercial propositions. Project partners on the programme include Cambridge Cognition, King’s College London, University of Sussex and Imperial College London. The company is led by CEO Derek Hill and is backed by Imperial Innovations Group plc (AIM: IVO).

Total raised

$3M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2012